Incurable, progressive Merkel cell carcinoma: A single‐institution study of 54 cases

Incurable, progressive Merkel cell carcinoma: A single‐institution study of 54 cases Key PointsThe median overall survival, disease‐free survival and survival from disease progression of patients with progressive disease were 15, 8 months and 5 months, respectively.Twenty‐two (96%) of 23 individuals suffering from disease progression died of the disease. The overall mortality rate was 70%.Patients with progressive MCC spend significantly more tumour‐related days in the hospital compared to patients without a progressive disease.The rate of immunosuppression was significantly higher in the MCC progressive group and those patients received more often radio‐ and/or chemotherapy.Despite an aggressive therapy approach and long hospitalisation, survival among patients suffering from progressive MCC was very poor. Randomised clinical trials are required to assess whether aggressive systemic and local therapy is justified in Merkel cell carcinoma patients with progressive disease.INTRODUCTIONMerkel cell carcinoma is an aggressive and fast‐growing neuroendocrine tumour of the skin. It occurs predominantly on sun‐exposed skin of elderly and/or immunosuppressed people.Approximately 4% of all patients with Merkel cell carcinoma initially present with distant metastases, a stage, where palliative treatment is usually considered. Very limited data are available on palliative treatment in patients suffering from Merkel cell carcinoma. A multimodal radio/chemotherapy concept is advisable for patients suffering from an advanced tumour stage or patients who are not http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Otolaryngology Wiley

Incurable, progressive Merkel cell carcinoma: A single‐institution study of 54 cases

Loading next page...
 
/lp/wiley/incurable-progressive-merkel-cell-carcinoma-a-single-institution-study-6s0YWX0AWl
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 John Wiley & Sons Ltd
ISSN
1749-4478
eISSN
1749-4486
D.O.I.
10.1111/coa.12996
Publisher site
See Article on Publisher Site

Abstract

Key PointsThe median overall survival, disease‐free survival and survival from disease progression of patients with progressive disease were 15, 8 months and 5 months, respectively.Twenty‐two (96%) of 23 individuals suffering from disease progression died of the disease. The overall mortality rate was 70%.Patients with progressive MCC spend significantly more tumour‐related days in the hospital compared to patients without a progressive disease.The rate of immunosuppression was significantly higher in the MCC progressive group and those patients received more often radio‐ and/or chemotherapy.Despite an aggressive therapy approach and long hospitalisation, survival among patients suffering from progressive MCC was very poor. Randomised clinical trials are required to assess whether aggressive systemic and local therapy is justified in Merkel cell carcinoma patients with progressive disease.INTRODUCTIONMerkel cell carcinoma is an aggressive and fast‐growing neuroendocrine tumour of the skin. It occurs predominantly on sun‐exposed skin of elderly and/or immunosuppressed people.Approximately 4% of all patients with Merkel cell carcinoma initially present with distant metastases, a stage, where palliative treatment is usually considered. Very limited data are available on palliative treatment in patients suffering from Merkel cell carcinoma. A multimodal radio/chemotherapy concept is advisable for patients suffering from an advanced tumour stage or patients who are not

Journal

Clinical OtolaryngologyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial